Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17392565 | 0.93 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL65675 | 0.93 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL13219346 | 0.93 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL6937576 | 0.88 | EPHX1 (0.56) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL2566080 | 0.86 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL25067967 | 0.85 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL2217468 | 0.85 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL9834472 | 0.85 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL20068603 | 0.85 | GPR119 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL14802583 | 0.84 | HPGD (0.39) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-119768738-A | Radiation-sensitive resin composition, pattern forming method, and radiation-sensitive acid generator | JSR株式会社 | 2025-04-04 | — | — | CN | disclosed |
| CN-119768740-A | Radiation-sensitive resin composition, pattern forming method, and radiation-sensitive acid generator | JSR株式会社 | 2025-04-04 | — | — | CN | disclosed |
| CN-119768739-A | Radiation-sensitive resin composition, pattern forming method, and radiation-sensitive acid generator | JSR株式会社 | 2025-04-04 | — | — | CN | disclosed |
| CN-118852104-A | Dihydro-quinoline-2-ketone compound and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11827603-B2 | Method for preparing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine | YUKI GOSEI KOGYO CO., LTD. (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20220388959-A1 | METHOD FOR PRODUCING 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4- MESYLOXYPIPERIDINE AND 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE | YUKI GOSEI KOGYO CO., LTD. (JP) | 2022-12-08 | — | — | US | disclosed |
| EP-3883928-A1 | GLP-1R AGONISTS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2021-04-20 | — | — | US | disclosed |
| EP-3741743-A1 | METHOD FOR PRODUCING 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE AND 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE | Yuki Gosei Kogyo Co., Ltd. (JP) | 2020-11-25 | — | — | EP | disclosed |
| CN-1656086-A | Benzofuran derivative | TANABE SEIYAKU CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| CN-1131228-C | Benzo (5,6) cyclohepta (1, 2-b) pyridine derivatives for inhibition of farnesyl protein transferase | SCHERING CORP (US) | 2003-12-17 | — | — | CN | disclosed |
| US-6440989-B2 | ANTITUMOR AGENT | SCHERING CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20010016585-A1 | Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase | AFONSO ADRIANO (IN) | 2001-08-23 | — | — | US | disclosed |
| US-6218401-B1 | FOR THERAPY OF PANCREATIC TUMOR CELLS, LUNG CANCER CELLS, MYELOID LEUKEMIA TUMOR CELLS, THYROID FOLLICULAR TUMOR CELLS, MYELODYSPLASTIC TUMOR CELLS, EPIDERMAL CARCINOMA TUMOR CELLS, BLADDER CARCINOMA TUMOR CELLS OR PROSTATE TUMOR CELLS | SCHERING CORPORATION | 2001-04-17 | — | — | US | disclosed |
| CN-1267291-A | Novel farnesyl protein transferase inhibitors of N-substituted ureas | SCHERING CORP (US) | 2000-09-20 | — | — | CN | disclosed |
| CN-1267294-A | Benzo (5,6) cyclohepta (1,2-b) pyridine derivs. for inhibition of farnesyl-protein transferase | SCHERING CORP (US) | 2000-09-20 | — | — | CN | disclosed |
| CN-1267292-A | Phenyl-substd. tricyclic inhibitors of farnesyl-protein transferase | SCHERING CORP (US) | 2000-09-20 | — | — | CN | disclosed |
| EP-0989981-A1 | NOVEL PHENYL-SUBSTITUTED TRICYCLIC INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1998057950-A1 | NOVEL PHENYL-SUBSTITUTED TRICYCLIC INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016585-A1 | Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase | FNTA, FNTB, HRAS | HPGD 1679/4885RECQL 2897/4885EPHX1 1604/4885 |
| US-11827603-B2 | Method for preparing 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine and 1-(1-tert-butoxycarbonyl-4-piperidylacetyl)-4-mesyloxypiperidine | AP2A1, TERT, APEH | HPGD 1278/4885RECQL 4462/4885EPHX1 851/4885 |
| US-20220388959-A1 | METHOD FOR PRODUCING 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4- MESYLOXYPIPERIDINE AND 1-(1-TERT-BUTOXYCARBONYL-4-PIPERIDYLACETYL)-4-MESYLOXYPIPERIDINE | TERT, APEH, AP2A1 | HPGD 863/4885RECQL 4539/4885EPHX1 679/4885 |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | HPGD 355/4885RECQL 173/4885EPHX1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.